DHR earnings
DANAHER CORP /DE/ — automated research on every print, the model's read of every earnings call, and the numbers against estimates.
| Reported | EPS | Consensus | Surprise |
|---|---|---|---|
| Jul 21, 2026 | 1.94 | 1.85 | +4.9% |
| Apr 21, 2026 | 2.06 | 1.94 | +6.2% |
| Jan 28, 2026 | 2.23 | 2.16 | +3.2% |
| Oct 21, 2025 | 1.89 | 1.72 | +9.9% |
DANAHER CORP /DE/ reported Q2 FY2026. EPS came in at $1.94 against a $1.85 consensus, beat by 4.9%. Revenue was $6.3B versus $6.1B expected, beat by 2.4%. Gross margin was 57.6%, down 270 bps from last quarter.
read the full report →Danaher [DANAHER CORP /DE/] reported a mixed Q1 FY2026, with EPS beating estimates by 6.2% while revenue fell short by 0.5%. The company's strong margin performance and positive outlook for the full year suggest that it is well-positioned to navigate ongoing market challenges.
read the full report →DANAHER CORP /DE/ cleared the quarter by only +0.4% on revenue and +3.2% on EPS, so the actionable read is not the beat. The variant perception is that 2026 guidance embeds a consumables-led bioprocess recovery with equipment only “approximately flat,” which makes the setup more durable than a capital-spending rebound narrative but less helpful to semiconductor filtration demand than a headline recovery might imply.
read the full report →DANAHER CORP /DE/ cleared the quarter on EPS, but the investable point is not the $6.05 billion revenue print. The market was set up for a modest top-line beat and got one; the variant view is that 2026 estimates should give more credit to self-help, because management put a $250 million savings number and a $0.30 EPS tailwind behind a still-muted 3% to 6% core-growth framework.
read the full report →- Sees FY adjusted earnings per share $8.45-$8.60.